Clinical trials: Hep A
Hepatitis B
HEPSERA Post Marketing Surveillance
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of adefovir dipivoxil administered in Korean CHB patients according to the prescribing information
- Trial name
- HEPSERA PMS (NCT01329419)
- Testing
- adefovir dipivoxil
- Volunteers
- 4,393 people
- Sponsor
- GlaxoSmithKline
Acute Alcoholic Hepatitis
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91.
- Trial name
- NCT02612428
- Testing
- ELAD System, Standard of Care (Control)
- Where
- 44 sites in United States, Austria and 4 more
- Volunteers
- 151 people
- Sponsor
- Vital Therapies, Inc.
HCV Infection
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.
- Trial name
- NCT00696904
- Testing
- ABT-333
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatitis B
Hepatitis B Challenge Dose in Adults (V232-059-10)
The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 month following a challenge dose…
- Trial name
- NCT01251276
- Testing
- Modified Process Hepatitis B Vaccine
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.
- Trial name
- NCT04189276
- Testing
- ETV/TDF+T101 No.1, ETV/TDF+T101 No.2, ETV or TDF
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Hepatitits C
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
The purpose of this study is to evaluate sustained virologic response 12 weeks after the end of treatment (SVR12) following 12 weeks of simeprevir plus sofosbuvir with and without ribavirin (RBV) and 24 weeks of simeprevir plus…
- Trial name
- GALAXY (NCT02165189)
- Testing
- Simeprevir, Sofosbuvir, Ribavirin
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Janssen Scientific Affairs, LLC
Hepatitis C Virus
Two-way Interaction Between Alisporivir and EDP239
The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients.
- Trial name
- NCT02173574
- Testing
- DEB025, EDP239
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis B
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with Nonalcoholic fatty liver
- Trial name
- NCT03604016
- Testing
- Besifovir dipivoxil, L-carnitine, Tenofovir Alafenamide
- Volunteers
- 76 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss and seroconversion in participants who stop tenofovir disoproxil fumarate (TDF) (Stop TDF arm) compared to participants who continue TDF…
- Trial name
- FINITE CHB (NCT01320943)
- Testing
- TDF, Stop TDF
- Where
- 13 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic…
- Trial name
- PILLAR (NCT00882908)
- Testing
- TMC435, Ribavirin (R), PegIFNα-2a (P)
- Where
- 71 sites in United States, Australia and 11 more
- Volunteers
- 386 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
This Registry is designed to obtain long term data on participants who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored…
- Trial name
- NCT01457768
- Where
- 323 sites in United States, Australia and 14 more
- Volunteers
- 570 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses.
- Trial name
- NCT05717686
- Testing
- AHB-137 injection
- Where
- 9 sites in United States, Hong Kong and 2 more
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AusperBio Therapeutics Inc.
Chronic Hepatitis b
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
This is a pilot study to determine the safety and efficacy of a novel adjuvanted hepatitis B virus (HBV) vaccine formulated as a potential therapeutic vaccine against chronic HBV infection.
- Trial name
- HBV003 (NCT03038802)
- Testing
- Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Vaxine Pty Ltd
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
- Trial name
- PK (NCT01708889)
- Testing
- BMS-914143 (Peginterferon Lambda-1a)
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis Delta Virus Infection
A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05861674
- Testing
- HH-003(20mg/kg), HH-003(10mg/kg), TAF
- Where
- 7 sites in China, Pakistan
- Volunteers
- 101 people
- Sponsor
- Huahui Health
Hepatitis C Virus
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a…
- Trial name
- PEDESTAL (NCT01598090)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 104 sites in United States, Austria and 13 more
- Volunteers
- 881 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Genotype 1 Chronic Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects.
- Trial name
- NCT00606086
- Testing
- GI-5005, Pegylated Interferon and Ribavirin
- Where
- 25 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlobeImmune
Chronic Hepatitis B
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
- Trial name
- NCT06425341
- Testing
- HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hepatitis C
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
- Trial name
- NCT02515279
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- Austria
- Volunteers
- 463 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.